This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Series

Jing Li, MD, PhD, MBA
Senior Vice President, Biologics Discovery at WuXi Biologics


Dr. Jing Li is currently the Senior Vice President of WuXi Biologics, leading the Biologics Discovery Division.

He joined WuXi AppTec in 2013 as Vice President of Biologics Discovery. Since then Dr. Li has formed a first class biologics drug discovery team in China, built up proprietary multiple comprehensive biologics drug discovery platforms, established the working process from target all the way to IND filing, and serviced both domestic and global clients by this open, fully integrated biologics R&D platform. Several programs have submitted IND filings and four have been approved for clinical trials in China or Australia. Several programs have been successfully out-licensed and one to an US Biotech with aggregated payments of $816mm.

Before joining WuXi AppTec, he worked in Novartis Biologics Center as Senior Manager of Portfolio & Alliance Management. Before that, he worked in Novartis Oncology as Lab Head and Program Team Head. Prior to Novartis, he worked in Wyeth (now Pfizer) as Senior Scientist and Project Leader.

He received his M.D. and Ph.D. degree in molecular immunology and oncology from Peking University Health Science Center (the former Beijing Medical University), and MBA degree from Yale University School of Management. He has more than 20+ years of professional experience in antibody engineering and 17+ years of industry experience in drug discovery and development.